Professional Education; and 93.118, Acquired Immunodeficiency Syndrome (AIDS) activities.

Other Requirements

Confidentiality

Applicants must have in place systems to ensure the confidentiality of all patient records.

Pre- and Post-test Counseling and Partner Notification

Recipients are required to provide HIV antibody testing to determine a person's HIV infection status; therefore, they must comply with state laws and regulations and CDC guidelines regarding pre- and post-test counseling and partner notification of HIV-seropositive patients, a copy of which will be included in the application kit. Recipients must also comply with state and local health department requirements relating to specific reportable diseases or conditions. Recipients must provide referrals for HIV diagnosis and treatment.

Paperwork Reduction Act

Projects that involve the collection of information from 10 or more individuals and funded by cooperative agreement will be subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act.

Human Subjects

The applicant must comply with the Department of Health and Human Services regulations (45 CFR part 46) regarding the protection of human subjects. Assurances must be provided to demonstrate that the project will be subject to initial and continuing review by an appropriate institutional review committee. The applicant will be responsible for providing assurance in accordance with the appropriate guidelines and form provided in the application kit.

HIV/AIDS Requirements

Recipients must comply with the document entitled "Content of AIDS-Related Written Materials, Pictorials, Audiovisuals, Questionnaires, Survey Instruments, and Educational Sessions" (June 1992), a copy of which is included in the application kit. In complying with the requirements for a program review panel, recipients are encouraged to use an existing program review panel such as the one created by the state health department's HIV/AIDS prevention program. If the recipient forms its own program review panel, at least one member must be an employee (or a designated representative) of a government health department consistent with the Content guidelines. The names of the review panel members must be listed on the Assurance of Compliance form CDC 0.113, which also will be included in the application kit. The recipient must submit the program review panel's report that indicates all materials have been reviewed and approved.

Application and Submission Deadline

The original and two copies of the application (Form PHS–5161–1) must be submitted to Elizabeth M. Taylor, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control, 255 East Paces Ferry Road, NE., room 300, Mailstop E–14, Atlanta, GA 30305 on or before September 11, 1992.

A. Deadline

Applications shall be considered as meeting the deadline if they are:

1. Received on or before the deadline date, or

2. Sent on or before the deadline date and received in time for submission to the independent review committee. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks will not be acceptable as proof of timely mailing.)

B. Late Applications

Applications that do not meet the criteria in A.1. or A.2. are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicant.

Where to Obtain Additional Information

A complete program description and information on application procedures, an application package, and business management technical assistance may be obtained from Lynn Mercer, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control, 255 East Paces Ferry Road, NE., room 300, Atlanta, GA 30305, (404) 842–6814.

Programmatic technical assistance may be obtained from Lawrence J. Geiter, Division of Tuberculosis Control, National Center for Prevention Services, Centers for Disease Control, Atlanta, GA 30333, (404) 639–2530.

Please refer to Announcement 261, HIV-Related Tuberculosis Preventive Therapy Regimen (PRT) Demonstration Cooperative Agreements, when requesting information or submitting an application.

Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017–001–00474–0) or Healthy People 2000 (Summary Report, Stock No. 017–001–00473–1) referenced in the introduction of this document through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325 (Telephone (202) 783–3238).

Dated: August 4, 1992.

Robert L. Foster,

Acting Associate Director for Management and Operations, Centers for Disease Control.

[FR Doc. 92–18857 Filed 8–7–92; 8:45 am]

BILLING CODE 4150–18–M

Food and Drug Administration

[Docket No. 92C–0293]

The Cosmetic, Toiletry, and Fragrance Association; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the Cosmetic, Toiletry, and Fragrance Association (CTFA) has filed a petition proposing that the color additive regulations be amended to provide for the safe use of FD&C Yellow No. 5 and its lakes for coloring drugs and cosmetics intended for use in the area of the eye.

FOR FURTHER INFORMATION CONTACT: Wesley Long, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C St. SW.,Washington, DC 20204, 202–254–9515.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 706(d)(1) (21 U.S.C. 376(d)(1))), notice is given that a petition (CAP 6C0205) has been filed by CTFA, 1101 17th St. NW., Suite 300, Washington, DC 20036. The petition proposes to amend the color additive regulations in §§ 74.1705 *FD&C Yellow No. 5* and 74.2705 *FD&C Yellow No. 5* (21 CFR 74.1705 and 74.2705) to provide for the safe use of FD&C Yellow No. 5 and its lakes for coloring drugs and cosmetics intended for use in the area of the eye.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be

published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 4, 1992.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92-18854 Filed 8-7-92; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 92F-0285]

Mitsui Toatsu Chemicals, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a petition has been filed on behalf of Mitsui Toatsu Chemicals, Inc., proposing that the food additive regulations be amended to provide for the expanded safe use of bis(*p*-ethylbenzylidene) sorbitol as a clarifying agent for polypropylene articles intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-254-9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 2B4330) has been filed on behalf of Mitsui Toatsu Chemicals, Inc., c/o 1001 G St. NW., Suite 500 West, Washington, DC 20001. The petition proposes to amend the food additive regulations in § 178.3295 *Clarifying agents for polymers* (21 CFR 178.3295) to provide for the expanded safe use of bis(*p*-ethylbenzylidene) sorbitol as a clarifying agent for polypropylene articles intended for use in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 4, 1992.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92-18855 Filed 8-7-92; 8:45 am]

BILLING CODE 4160-01-F

Request for Nominations for Members on Public Advisory Committees; Science Board to the Food and Drug Administration

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for 10 members to serve on the Science Board (the board) to the Food and Drug Administration in the Office of the Commissioner. Elsewhere in this issue of the **Federal Register**, FDA is publishing a final rule announcing the establishment of this committee.

DATES: Nominations should be received on or before September 9, 1992.

ADDRESSES: All nominations for membership except for the consumer-nominated members should be sent to Susan L. Crandall (address below). All nominations for the consumer-nominated members should be sent to Phyllis Weller (address below).

FOR FURTHER INFORMATION CONTACT:

Regarding all nominations for membership, except for the consumer-nominated members: Susan L. Crandall, Office of the Commissioner (HF-33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5839.

Regarding all nominations for the consumer-nominated members: Phyllis Weller, Office of Consumer Affairs (HFE-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5006.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for 10 members to serve on the board. The function of the board is to provide advice primarily to the agency's Senior Science Advisor and, as needed, the Commissioner and other appropriate officials on specific complex and technical issues as well as emerging issues within the scientific community in academia and industry. Additionally, the board will provide advice to the agency on keeping pace with technical and scientific evolutions in the fields of regulatory science, on formulating an appropriate research agenda, and on upgrading its scientific and research facilities to keep pace with these changes. It will also provide the means for critical review of the agency sponsored intramural and extramural scientific research programs.

FDA is notifying the public that the agency's Senior Science Advisor, Elkan Blout, has prepared a list of prospective candidates from academia and industry. These individuals will be considered along with other nominations submitted to the agency in response to this Federal Register notice.

Persons nominated for membership shall be knowledgeable in the fields of chemistry, pharmacology, toxicology, clinical research, and other scientific disciplines. Members shall represent academia and industry. The committee may include one technically qualified member who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. Members shall be invited to serve for overlapping 4-year terms except for the first members appointed: Three shall serve for a term of 2 years, three for a term of 3 years, and four for a term of 4 years as designated at the time of appointment.

Interested persons may nominate one or more qualified persons for membership on the advisory committee. Nominations shall state that the nominee is willing to serve as a member of the advisory committee and appears to have no conflict of interest that would preclude committee membership. Potential candidates will be asked by FDA to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest.

Selection of a representative of consumer interests is conducted through procedures that include use of a consortium of consumer organizations which has the responsibility for screening, interviewing, and recommending candidates for the agency's selection. Candidates, like all other candidates for membership on the committee, should possess appropriate qualifications to understand and contribute to the committee's work.

FDA has special interest in assuring that women, minority groups, and the physically handicapped are adequately represented on advisory committees and therefore extends particular encouragement to nominations for appropriately qualified female, minority, or physically handicapped candidates.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. App. 2) and 21 CFR Part 14, relating to advisory committees.

Dated: August 3, 1992.

Michael R. Taylor,

Deputy Commissioner for Policy.

[FR Doc. 92-18817 Filed 8-7-92; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

John E. Fogarty International Center for Advanced Study in the Health Sciences; Meeting of the Fogarty International Center Advisory Board

Pursuant to Public Law 92-463, notice is hereby given of the twenty-second meeting of the Fogarty International Center (FIC) Advisory Board, September 22, 1992, in the Lawton Chiles International House (Building 16), at the National Institutes of Health.

The meeting will be open to the public from 8:30 a.m. to 2:30 p.m. The morning agenda will include a report by the Director, FIC, a report on the meeting of the Advisory Committee to the NIH Director, a presentation on planning for future directions of the FIC, and a report on international collaboration in vaccine development.

The afternoon agenda will include a presentation by the Director, NIH.

In accordance with the provisions of secs. 552b(c)(4) and 552b(c)(6), title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public from 2:30 p.m. to adjournment for the review of applications for International Research Fellowships, Senior International Fellowships, and Fogarty International Research Collaboration Awards.

Myra Halem, Committee Management Assistant, Fogarty International Center, Building 31, room B2C08, National Institutes of Health, Bethesda, Maryland 20892 (301-496-1491), will provide a summary of the meeting and a roster of the committee members upon request.

Dr. Coralie Farlee, Assistant Director for International Legislation and Advisory Activities, Fogarty International Center (Executive Secretary), Building 31, room B2C08, telephone 301-496-1491, will provide substantive program information.

Catalog of Federal Domestic Assistance Program No. 93.154, Special International Postdoctoral Research Program in Acquired Immunodeficiency Syndrome and No. 93.989, Senior International Awards Program.

Dated: July 30, 1992.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 92-18883 Filed 8-7-92; 8:45 am]

BILLING CODE 4140-01-M

National Center for Research Resources; Meeting of the National Advisory Research Resources Council

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the National Advisory Research Resources Council (NARRC), National Center for Research Resources (NCRR), at the National Institutes of Health.

This meeting will be open to the public, as indicated below, during which time there will be discussions on administrative matters such as previous meeting minutes; the report of the Director, NCRR; and review of budget and legislative updates. Attendance by the public will be limited to space available.

In accordance with provisions set forth in secs. 552b(c) (4) and 552b(c) (6), title 5, U.S. Code and sec. 10(d) of Public Law 92-463, the meeting will be closed to the public as listed below for the review, discussion and evaluation of individual grant applications. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Research Resources Council.

Date of Meeting: September 9-11, 1992.

Place of Meeting: National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892.

Open: September 9, 6:45 p.m. until recess, Planning and Agenda Subcommittee, Building 12A, room 4007. September 10, 9 a.m. until recess, Conference Room 6, Building 31C.

Closed: September 11, 8 a.m. until 10 a.m., Conference Room 6, Building 31C.

Open: September 11, 10 a.m. until adjournment, Conference Room 6, Building 31C.

Mr. James J. Doherty, Information Office, NCRR, Westwood Building, room 10A15, National Institutes of Health, Bethesda, Maryland 20892, (301) 496-5545, will provide a summary of meeting and a roster of the Council members upon request. Dr. Judith L. Vaitukaitis, Deputy Director for Extramural Research Resources, NCRR, Building 12A, room 4011, National Institutes of Health, Bethesda, Maryland 20892, (301) 496-6023, will furnish substantive program information upon request, and will receive any comments pertaining to this announcement.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, Laboratory Animal Sciences and Primate Research; 93.333, Clinical Research; 93.337, Biomedical Research Support; 93.371, Biomedical Research Technology; 93.389, Research Centers in Minority Institutions; 93.198, Biological Models and Materials Research; 93.167, Research Facilities Improvement Program; National Institutes of Health.)

Dated: July 30, 1992.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 92-18884 Filed 8-7-92; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Meetings

Pursuant to Public Law 92-463, notice is hereby given of the meetings of the following Heart, Lung, and Blood Special Emphasis Panels.

The meeting will be open to the public to discuss administrative details relating to Special Emphasis Panel (SEP) business for approximately one half hour at the beginning of each meeting. Attendance by the public will be limited to space available. The meetings will be closed thereafter in accordance with the provisions set forth in sec. 552b(c)(4) and 552(c)(6), title 5, U.S.C. and sec. 10(d) of Public Law 92-463, for the review, discussion and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

The Office of Committee Management, National Heart, Lung, and Blood Institute, Westwood Building, room 7A15, National Institutes of Health, Bethesda, Maryland 20892, telephone 301-496-7548, will furnish summaries of the meetings and rosters of panel members. Substantive program information may be obtained from each Scientific Review Administrator whose telephone number is provided. Since it is necessary to schedule meetings well in advance, it is suggested that anyone planning to attend a meeting contact the Scientific Review Administrator to confirm the exact date, time and location.

Name of Panel: Institutional Short-Term Training for Minority Students (T35-M).

Scientific Review Administrator: Dr. Dennis Lang, Telephone 301-496-8818.

Dates of Meeting: August 17, 1992.

Place of Meeting: Westwood Building, room 550 (Telephone Conference).